DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Dong Hyun | ko |
dc.contributor.author | Kim, Sung Hyun | ko |
dc.contributor.author | Kim, Daejin | ko |
dc.contributor.author | Kim, Jin Hyoung | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.contributor.author | Kim, Jeong Hun | ko |
dc.date.accessioned | 2014-08-29T01:32:19Z | - |
dc.date.available | 2014-08-29T01:32:19Z | - |
dc.date.created | 2014-04-07 | - |
dc.date.created | 2014-04-07 | - |
dc.date.issued | 2014-03 | - |
dc.identifier.citation | BIOMATERIALS, v.35, no.9, pp.3052 - 3059 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.uri | http://hdl.handle.net/10203/188789 | - |
dc.description.abstract | Age-related macular degeneration and diabetic retinopathy are leading causes of blindness. Vascular endothelial growth factor (VEGF) is known to be the main factor that induces pathological angiogenesis in these diseases. In this study, we investigate the therapeutic potential and safety profiles of high-affinity peptides targeting VEGF which are identified using an 'aptide' technology. We show that two VEGF-binding aptides, APT(VEGF1) and APT(VEGF2), demonstrate high binding affinity and specificity to VEGF. Furthermore, they suppress VEGF-induced activation of VEGF receptor-2, in vitro angiogenesis, and in vivo pathological choroidal and retinal neovascularization. Despite potent anti-angiogenic effects, both VEGF-binding aptides do not induce any definite toxicity at the level of cellular viability, histological integrity, and gene expression. Our data show the therapeutic potential of VEGF-binding peptides for the treatment of choroidal and retinal neovascularization. | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject | OXYGEN-INDUCED RETINOPATHY | - |
dc.subject | LARGE GENE LISTS | - |
dc.subject | MACULAR DEGENERATION | - |
dc.subject | VASCULAR-PERMEABILITY | - |
dc.subject | DIABETIC-RETINOPATHY | - |
dc.subject | BEVACIZUMAB | - |
dc.subject | ANGIOGENESIS | - |
dc.subject | RANIBIZUMAB | - |
dc.subject | AFLIBERCEPT | - |
dc.title | VEGF-binding aptides and the inhibition of choroidal and retinal neovascularization | - |
dc.type | Article | - |
dc.identifier.wosid | 000332188900049 | - |
dc.identifier.scopusid | 2-s2.0-84894989799 | - |
dc.type.rims | ART | - |
dc.citation.volume | 35 | - |
dc.citation.issue | 9 | - |
dc.citation.beginningpage | 3052 | - |
dc.citation.endingpage | 3059 | - |
dc.citation.publicationname | BIOMATERIALS | - |
dc.identifier.doi | 10.1016/j.biomaterials.2013.12.031 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.contributor.nonIdAuthor | Jo, Dong Hyun | - |
dc.contributor.nonIdAuthor | Kim, Jin Hyoung | - |
dc.contributor.nonIdAuthor | Kim, Jeong Hun | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Pathological angiogenesis | - |
dc.subject.keywordAuthor | Vascular endothelial growth factor | - |
dc.subject.keywordAuthor | Choroidal neovascularization | - |
dc.subject.keywordAuthor | Retinal neovascularization | - |
dc.subject.keywordAuthor | Age-related macular degeneration | - |
dc.subject.keywordAuthor | Diabetic retinopathy | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | OXYGEN-INDUCED RETINOPATHY | - |
dc.subject.keywordPlus | LARGE GENE LISTS | - |
dc.subject.keywordPlus | MACULAR DEGENERATION | - |
dc.subject.keywordPlus | VASCULAR-PERMEABILITY | - |
dc.subject.keywordPlus | DIABETIC-RETINOPATHY | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | RANIBIZUMAB | - |
dc.subject.keywordPlus | AFLIBERCEPT | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.